Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
However, there are few reports of serious side effects
J.LimdiJ
4c) and the interaction with integrin receptors Itga5 and Itgb1 was lost (Supplementary Fig
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal toxicology shows wide therapeutic window Injection-site reactions reported anecdotally Known interactions Anticoagulants (theoretical, due to angiogenic activity unstudied) Contraindications Active malignancy (theoretical, due to angiogenic mechanism) Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A
US$ 20.68
US$ 22.10
US$ 22.61
US$ 27.12
US$ 24.08
US$ 26.21
US$ 27.21
